PMC5558853

The ABFM regimen in AYA patients caused significant asparaginase-related toxicities including grade 3-4 hepatotoxicity in 41%, pancreatitis in 11%, osteonecrosis in 9%, thrombosis in 19%, and severe a

Effect: adverse; Grade 3-4 liver enzyme elevations in 41%

The ABFM regimen in AYA patients caused significant asparaginase-related toxicities including grade 3-4 hepatotoxicity in 41%, pancreatitis in 11%, osteonecrosis in 9%, thrombosis in 19%, and severe a

Effect: adverse; Grade 3-4 liver enzyme elevations in 41%

The ABFM regimen in AYA patients caused significant asparaginase-related toxicities including grade 3-4 hepatotoxicity in 41%, pancreatitis in 11%, osteonecrosis in 9%, thrombosis in 19%, and severe a

Effect: adverse; Grade 3-4 liver enzyme elevations in 41%

The ABFM regimen in AYA patients caused significant asparaginase-related toxicities including grade 3-4 hepatotoxicity in 41%, pancreatitis in 11%, osteonecrosis in 9%, thrombosis in 19%, and severe a

Effect: adverse; Grade 3-4 liver enzyme elevations in 41%

The ABFM regimen in AYA patients caused significant asparaginase-related toxicities including grade 3-4 hepatotoxicity in 41%, pancreatitis in 11%, osteonecrosis in 9%, thrombosis in 19%, and severe a

Effect: adverse; Grade 3-4 liver enzyme elevations in 41%

The ABFM regimen in AYA patients caused significant asparaginase-related toxicities including grade 3-4 hepatotoxicity in 41%, pancreatitis in 11%, osteonecrosis in 9%, thrombosis in 19%, and severe a

Effect: adverse; Grade 3-4 liver enzyme elevations in 41%

The ABFM regimen in AYA patients caused significant asparaginase-related toxicities including grade 3-4 hepatotoxicity in 41%, pancreatitis in 11%, osteonecrosis in 9%, thrombosis in 19%, and severe a

Effect: adverse; Grade 3-4 liver enzyme elevations in 41%

The ABFM regimen in AYA patients caused significant asparaginase-related toxicities including grade 3-4 hepatotoxicity in 41%, pancreatitis in 11%, osteonecrosis in 9%, thrombosis in 19%, and severe a

Effect: adverse; Grade 3-4 liver enzyme elevations in 41%

The ABFM regimen in AYA patients caused significant asparaginase-related toxicities including grade 3-4 hepatotoxicity in 41%, pancreatitis in 11%, osteonecrosis in 9%, thrombosis in 19%, and severe a

Effect: adverse; Grade 3-4 liver enzyme elevations in 41%

The ABFM regimen in AYA patients caused significant asparaginase-related toxicities including grade 3-4 hepatotoxicity in 41%, pancreatitis in 11%, osteonecrosis in 9%, thrombosis in 19%, and severe a

Effect: adverse; Grade 3-4 liver enzyme elevations in 41%

The ABFM regimen in AYA patients caused significant asparaginase-related toxicities including grade 3-4 hepatotoxicity in 41%, pancreatitis in 11%, osteonecrosis in 9%, thrombosis in 19%, and severe a

Effect: adverse; Grade 3-4 liver enzyme elevations in 41%

The ABFM regimen in AYA patients caused significant asparaginase-related toxicities including grade 3-4 hepatotoxicity in 41%, pancreatitis in 11%, osteonecrosis in 9%, thrombosis in 19%, and severe a

Effect: adverse; Grade 3-4 liver enzyme elevations in 41%

The ABFM regimen in AYA patients caused significant asparaginase-related toxicities including grade 3-4 hepatotoxicity in 41%, pancreatitis in 11%, osteonecrosis in 9%, thrombosis in 19%, and severe a

Effect: adverse; Grade 3-4 liver enzyme elevations in 41%

The ABFM regimen in AYA patients caused significant asparaginase-related toxicities including grade 3-4 hepatotoxicity in 41%, pancreatitis in 11%, osteonecrosis in 9%, thrombosis in 19%, and severe a

Effect: adverse; Grade 3-4 liver enzyme elevations in 41%

The ABFM regimen in AYA patients caused significant asparaginase-related toxicities including grade 3-4 hepatotoxicity in 41%, pancreatitis in 11%, osteonecrosis in 9%, thrombosis in 19%, and severe a

Effect: adverse; Grade 3-4 liver enzyme elevations in 41%

The ABFM regimen in AYA patients caused significant asparaginase-related toxicities including grade 3-4 hepatotoxicity in 41%, pancreatitis in 11%, osteonecrosis in 9%, thrombosis in 19%, and severe a

Effect: adverse; Grade 3-4 liver enzyme elevations in 41%

The ABFM regimen in AYA patients caused significant asparaginase-related toxicities including grade 3-4 hepatotoxicity in 41%, pancreatitis in 11%, osteonecrosis in 9%, thrombosis in 19%, and severe a

Effect: adverse; Grade 3-4 liver enzyme elevations in 41%

The ABFM regimen in AYA patients caused significant asparaginase-related toxicities including grade 3-4 hepatotoxicity in 41%, pancreatitis in 11%, osteonecrosis in 9%, thrombosis in 19%, and severe a

Effect: adverse; Grade 3-4 liver enzyme elevations in 41%

The ABFM regimen in AYA patients caused significant asparaginase-related toxicities including grade 3-4 hepatotoxicity in 41%, pancreatitis in 11%, osteonecrosis in 9%, thrombosis in 19%, and severe a

Effect: adverse; Grade 3-4 liver enzyme elevations in 41%

The ABFM regimen in AYA patients caused significant asparaginase-related toxicities including grade 3-4 hepatotoxicity in 41%, pancreatitis in 11%, osteonecrosis in 9%, thrombosis in 19%, and severe a

Effect: adverse; Grade 3-4 liver enzyme elevations in 41%

The ABFM regimen in AYA patients caused significant asparaginase-related toxicities including grade 3-4 hepatotoxicity in 41%, pancreatitis in 11%, osteonecrosis in 9%, thrombosis in 19%, and severe a

Effect: adverse; Grade 3-4 liver enzyme elevations in 41%

The ABFM regimen in AYA patients caused significant asparaginase-related toxicities including grade 3-4 hepatotoxicity in 41%, pancreatitis in 11%, osteonecrosis in 9%, thrombosis in 19%, and severe a

Effect: adverse; Grade 3-4 liver enzyme elevations in 41%

The ABFM regimen in AYA patients caused significant asparaginase-related toxicities including grade 3-4 hepatotoxicity in 41%, pancreatitis in 11%, osteonecrosis in 9%, thrombosis in 19%, and severe a

Effect: adverse; Grade 3-4 liver enzyme elevations in 41%

The ABFM regimen in AYA patients caused significant asparaginase-related toxicities including grade 3-4 hepatotoxicity in 41%, pancreatitis in 11%, osteonecrosis in 9%, thrombosis in 19%, and severe a

Effect: adverse; Grade 3-4 liver enzyme elevations in 41%

The ABFM regimen in AYA patients caused significant asparaginase-related toxicities including grade 3-4 hepatotoxicity in 41%, pancreatitis in 11%, osteonecrosis in 9%, thrombosis in 19%, and severe a

Effect: adverse; Grade 3-4 liver enzyme elevations in 41%

The ABFM regimen in AYA patients caused significant asparaginase-related toxicities including grade 3-4 hepatotoxicity in 41%, pancreatitis in 11%, osteonecrosis in 9%, thrombosis in 19%, and severe a

Effect: adverse; Grade 3-4 liver enzyme elevations in 41%

The ABFM regimen in AYA patients caused significant asparaginase-related toxicities including grade 3-4 hepatotoxicity in 41%, pancreatitis in 11%, osteonecrosis in 9%, thrombosis in 19%, and severe a

Effect: adverse; Grade 3-4 liver enzyme elevations in 41%

MRD-negative status by flow cytometry at Day 29 and Day 84 of chemotherapy was strongly prognostic of long-term survival in AYA patients with ALL treated on both ABFM and hyper-CVAD, with Day 29 MRD-n

Effect: improvement; 5-year OS 75% MRD-negative vs 40% MRD-positive at Day 29

MRD-negative status by flow cytometry at Day 29 and Day 84 of chemotherapy was strongly prognostic of long-term survival in AYA patients with ALL treated on both ABFM and hyper-CVAD, with Day 29 MRD-n

Effect: improvement; 5-year OS 75% MRD-negative vs 40% MRD-positive at Day 29

MRD-negative status by flow cytometry at Day 29 and Day 84 of chemotherapy was strongly prognostic of long-term survival in AYA patients with ALL treated on both ABFM and hyper-CVAD, with Day 29 MRD-n

Effect: improvement; 5-year OS 75% MRD-negative vs 40% MRD-positive at Day 29

MRD-negative status by flow cytometry at Day 29 and Day 84 of chemotherapy was strongly prognostic of long-term survival in AYA patients with ALL treated on both ABFM and hyper-CVAD, with Day 29 MRD-n

Effect: improvement; 5-year OS 75% MRD-negative vs 40% MRD-positive at Day 29

MRD-negative status by flow cytometry at Day 29 and Day 84 of chemotherapy was strongly prognostic of long-term survival in AYA patients with ALL treated on both ABFM and hyper-CVAD, with Day 29 MRD-n

Effect: improvement; 5-year OS 75% MRD-negative vs 40% MRD-positive at Day 29

MRD-negative status by flow cytometry at Day 29 and Day 84 of chemotherapy was strongly prognostic of long-term survival in AYA patients with ALL treated on both ABFM and hyper-CVAD, with Day 29 MRD-n

Effect: improvement; 5-year OS 75% MRD-negative vs 40% MRD-positive at Day 29

MRD-negative status by flow cytometry at Day 29 and Day 84 of chemotherapy was strongly prognostic of long-term survival in AYA patients with ALL treated on both ABFM and hyper-CVAD, with Day 29 MRD-n

Effect: improvement; 5-year OS 75% MRD-negative vs 40% MRD-positive at Day 29

MRD-negative status by flow cytometry at Day 29 and Day 84 of chemotherapy was strongly prognostic of long-term survival in AYA patients with ALL treated on both ABFM and hyper-CVAD, with Day 29 MRD-n

Effect: improvement; 5-year OS 75% MRD-negative vs 40% MRD-positive at Day 29

MRD-negative status by flow cytometry at Day 29 and Day 84 of chemotherapy was strongly prognostic of long-term survival in AYA patients with ALL treated on both ABFM and hyper-CVAD, with Day 29 MRD-n

Effect: improvement; 5-year OS 75% MRD-negative vs 40% MRD-positive at Day 29

MRD-negative status by flow cytometry at Day 29 and Day 84 of chemotherapy was strongly prognostic of long-term survival in AYA patients with ALL treated on both ABFM and hyper-CVAD, with Day 29 MRD-n

Effect: improvement; 5-year OS 75% MRD-negative vs 40% MRD-positive at Day 29

MRD-negative status by flow cytometry at Day 29 and Day 84 of chemotherapy was strongly prognostic of long-term survival in AYA patients with ALL treated on both ABFM and hyper-CVAD, with Day 29 MRD-n

Effect: improvement; 5-year OS 75% MRD-negative vs 40% MRD-positive at Day 29

MRD-negative status by flow cytometry at Day 29 and Day 84 of chemotherapy was strongly prognostic of long-term survival in AYA patients with ALL treated on both ABFM and hyper-CVAD, with Day 29 MRD-n

Effect: improvement; 5-year OS 75% MRD-negative vs 40% MRD-positive at Day 29

MRD-negative status by flow cytometry at Day 29 and Day 84 of chemotherapy was strongly prognostic of long-term survival in AYA patients with ALL treated on both ABFM and hyper-CVAD, with Day 29 MRD-n

Effect: improvement; 5-year OS 75% MRD-negative vs 40% MRD-positive at Day 29

MRD-negative status by flow cytometry at Day 29 and Day 84 of chemotherapy was strongly prognostic of long-term survival in AYA patients with ALL treated on both ABFM and hyper-CVAD, with Day 29 MRD-n

Effect: improvement; 5-year OS 75% MRD-negative vs 40% MRD-positive at Day 29

MRD-negative status by flow cytometry at Day 29 and Day 84 of chemotherapy was strongly prognostic of long-term survival in AYA patients with ALL treated on both ABFM and hyper-CVAD, with Day 29 MRD-n

Effect: improvement; 5-year OS 75% MRD-negative vs 40% MRD-positive at Day 29

MRD-negative status by flow cytometry at Day 29 and Day 84 of chemotherapy was strongly prognostic of long-term survival in AYA patients with ALL treated on both ABFM and hyper-CVAD, with Day 29 MRD-n

Effect: improvement; 5-year OS 75% MRD-negative vs 40% MRD-positive at Day 29

MRD-negative status by flow cytometry at Day 29 and Day 84 of chemotherapy was strongly prognostic of long-term survival in AYA patients with ALL treated on both ABFM and hyper-CVAD, with Day 29 MRD-n

Effect: improvement; 5-year OS 75% MRD-negative vs 40% MRD-positive at Day 29

MRD-negative status by flow cytometry at Day 29 and Day 84 of chemotherapy was strongly prognostic of long-term survival in AYA patients with ALL treated on both ABFM and hyper-CVAD, with Day 29 MRD-n

Effect: improvement; 5-year OS 75% MRD-negative vs 40% MRD-positive at Day 29

MRD-negative status by flow cytometry at Day 29 and Day 84 of chemotherapy was strongly prognostic of long-term survival in AYA patients with ALL treated on both ABFM and hyper-CVAD, with Day 29 MRD-n

Effect: improvement; 5-year OS 75% MRD-negative vs 40% MRD-positive at Day 29

MRD-negative status by flow cytometry at Day 29 and Day 84 of chemotherapy was strongly prognostic of long-term survival in AYA patients with ALL treated on both ABFM and hyper-CVAD, with Day 29 MRD-n

Effect: improvement; 5-year OS 75% MRD-negative vs 40% MRD-positive at Day 29

MRD-negative status by flow cytometry at Day 29 and Day 84 of chemotherapy was strongly prognostic of long-term survival in AYA patients with ALL treated on both ABFM and hyper-CVAD, with Day 29 MRD-n

Effect: improvement; 5-year OS 75% MRD-negative vs 40% MRD-positive at Day 29

MRD-negative status by flow cytometry at Day 29 and Day 84 of chemotherapy was strongly prognostic of long-term survival in AYA patients with ALL treated on both ABFM and hyper-CVAD, with Day 29 MRD-n

Effect: improvement; 5-year OS 75% MRD-negative vs 40% MRD-positive at Day 29

MRD-negative status by flow cytometry at Day 29 and Day 84 of chemotherapy was strongly prognostic of long-term survival in AYA patients with ALL treated on both ABFM and hyper-CVAD, with Day 29 MRD-n

Effect: improvement; 5-year OS 75% MRD-negative vs 40% MRD-positive at Day 29